生髮補充劑及治療產品市場機會、成長要素、產業趨勢分析及預測（2026-2035年）

2025 年全球生髮補充劑和治療市場價值 88 億美元，預計到 2035 年將達到 157 億美元，年複合成長率為 6.1%。

由於斑禿、脫髮症和其他頭皮疾病等頭髮問題的日益普遍，市場正經歷顯著擴張。消費者尋求有效的解決方案來改善自身形象並提升自信。頭髮脫髮症現象的加劇、整裝儀容意識的提高，以及透過零售和線上管道購買到經臨床驗證的非處方藥和處方藥，都進一步推動了市場需求。消費者現在更加重視預防性護髮、健康照護和經科學驗證的治療方法，因此營養補充品、外用產品和非侵入性治療設備的使用率不斷提高。意識的提高、產品的可及性以及技術的創新，使得生髮補充劑和療法成為現代個人護理和健康保健的重要組成部分。

這個市場涵蓋了旨在預防脫髮、促進頭髮生長和改善頭皮整體健康的各種產品。這些產品包括含有維生素、礦物質和植物萃取物的口服補充劑，以及外用藥物和藥物療法（包括處方藥和先進的非侵入性設備）。

預計到2025年，醫藥產業的銷售額將達到62億美元。這主要得益於市場對經臨床驗證的男性型脫髮症（雄性脫毛症）及其他類型脫髮症治療方法的需求不斷成長。口服藥物、外用藥物、注射和專用醫療設備因其高效性和顯著改善患者預後而持續受到關注。

預計到2035年，男性市場規模將達到104億美元，複合年成長率（CAGR）為5.9%。男性市場主導的主要原因是男性型脫髮症的高發生率，近一半男性在50歲時受到影響，而大多數男性在80歲時受到影響。便捷的營養補充劑，加上技術先進的外用療法以及雷射帽和頭皮刺激器等非侵入性設備，正在推動男性消費者對這些產品的接受度，並顯著促進市場成長。

預計到2025年，北美生髮補充劑和治療市場將佔據44.3%的市場佔有率，繼續保持主導主要得益於該地區較高的脫髮症率以及對創新治療方法的廣泛接受。藥品、膳食補充劑和非侵入性設備的進步，以及消費者對天然且經臨床驗證的護髮方案日益成長的偏好，都進一步推動了市場成長。便利的醫療保健基礎設施、消費者意識的提高以及監管支持，也進一步鞏固了北美的市場主導地位。

目錄

第1章：調查方法和範圍

第2章執行摘要

第3章業界考察

• 生態系分析
• 影響產業的因素
  • 促進因素
    • 脫髮症/禿髮盛行率增加
    • 消費者自我護理意識的提升與趨勢
    • 拓展電子商務和直接面對消費者的銷售管道
    • 治療技術和臨床研究的進展
  • 產業潛在風險與挑戰
    • 替代治療方法的選擇增多
    • 與藥物治療相關的擔憂
  • 市場機遇
    • 對個人化和精準解決方案的需求日益成長
    • 聯合治療和輔助解決方案的成長
• 成長潛力分析
• 監理情勢
• 管道分析
• 價格分析
• 未來市場趨勢
• 波特的分析
• PESTEL 分析

第4章 競爭情勢

• 介紹
• 企業市佔率分析
• 公司矩陣分析
• 主要市場公司的競爭分析
• 競爭定位矩陣
• 主要進展
  • 併購
  • 夥伴關係與合作
  • 新產品發布
  • 擴張計劃

第5章 市場估計與預測：依類型分類，2022-2035年

• 補充
  • 依產品類型
    • 單一成分補充劑
    • 複合成分補充劑
  • 按劑型
    • 粉末
    • 軟糖
    • 藥片
    • 膠囊
    • 液體
    • 其他
• 製藥
  • 口服藥物
  • 外用和注射製劑
  • 醫療設備

第6章 市場估計與預測：性別，2022-2035年

• 男性
• 女士

第7章 市場估價與預測：依通路分類，2022-2035年

• 醫院藥房
• 電子商務
  • 線上零售商
  • 品牌官方網站
• 零售藥房
• 藥局
• 其他

第8章 市場估計與預測：依地區分類，2022-2035年

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第9章：公司簡介

• Hair supplements
  • Amway Corporation
  • GNC Holdings
  • HUM Nutrition
  • 大自然的饋贈
  • Nutraceutical Wellness
  • OUAI Healthcare
  • Phyto
  • Viviscal Limited（Church &Dwight）
• Hair treatment
  • Cipla
  • Curallux
  • Eli Lilly and Company
  • ExoCoBio
  • Keranique
  • Kenvue
  • Lexington International
  • Merck
  • Pfizer

The Global Hair Growth Supplement and Treatment Market was valued at USD 8.8 billion in 2025 and is estimated to grow at a CAGR of 6.1% to reach USD 15.7 billion by 2035.

The market is witnessing strong expansion due to the rising prevalence of hair disorders such as alopecia areata, telogen effluvium, and other scalp conditions, driving consumers to seek effective solutions that enhance appearance and self-confidence. Increasing hair thinning, growing awareness around personal grooming, and the availability of clinically supported over-the-counter and prescription solutions across both retail and online channels are further fueling demand. Consumers are now prioritizing preventive hair care, wellness, and scientifically validated treatments, which has resulted in rising adoption of dietary supplements, topical solutions, and non-invasive therapeutic devices. The convergence of awareness, accessibility, and technological innovation is positioning hair growth supplements and treatments as a core component of modern personal care and healthcare routines.

The market includes a broad range of products designed to prevent hair loss, stimulate regrowth, and improve overall scalp health. This encompasses oral supplements containing vitamins, minerals, and botanical extracts, alongside topical and pharmaceutical therapies, which include prescription medications and advanced non-invasive devices.

The pharmaceuticals segment generated USD 6.2 billion in 2025, driven by the growing demand for clinically proven interventions for androgenetic alopecia and other forms of hair loss. Oral medications, topical solutions, injectables, and specialized devices continue to gain traction due to their high efficacy and improved patient outcomes.

The men segment is expected to reach USD 10.4 billion by 2035, growing at a CAGR of 5.9%. Male dominance is largely attributed to the high prevalence of androgenetic alopecia, with nearly half of men affected by age 50 and a significant majority by age 80. The convenience of supplements, coupled with technologically advanced topical treatments and non-invasive devices such as laser caps and scalp stimulators, has strengthened adoption among male consumers, contributing substantially to market growth.

North America Hair Growth Supplement and Treatment Market accounted for 44.3% share in 2025, maintaining leadership due to the region's high hair loss prevalence and strong adoption of innovative treatments. Growth is further supported by advances in pharmaceuticals, dietary supplements, and non-invasive devices, along with rising consumer preference for natural and clinically validated hair care solutions. The combination of accessible healthcare infrastructure, consumer awareness, and regulatory support underpins North America's dominant position.

Key players in the Global Hair Growth Supplement and Treatment Market include GNC Holdings, Cipla Limited, Amway Corporation, Pfizer, Nature's Bounty, HUM Nutrition, ExoCoBio, Eli Lilly and Company, OUAI Healthcare, Merck, Viviscal Limited (Church & Dwight), Kenvue, Lexington International, Curallux, Keranique, and Nutraceutical Wellness. Companies in this market are employing strategies such as investing heavily in R&D to create clinically validated and multi-functional products, expanding product portfolios to target gender-specific and age-specific needs, and leveraging advanced delivery technologies to improve efficacy. Strategic partnerships with dermatologists, wellness influencers, and online health platforms are used to enhance brand credibility and reach. Firms are also focusing on omnichannel distribution, combining e-commerce, retail, and subscription services to boost accessibility and retention, while emphasizing marketing campaigns centered on scientific validation, natural ingredients, and visible results to strengthen their market foothold and consumer trust.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research approach
• 1.3 Quality commitments
  • 1.3.1 GMI AI policy and data integrity commitment
    • 1.3.1.1 Source consistency protocol
• 1.4 Research trail and confidence scoring
  • 1.4.1 Research trail components
  • 1.4.2 Scoring components
• 1.5 Data collection
  • 1.5.1 Partial list of primary sources
• 1.6 Data mining sources
  • 1.6.1 Paid sources
    • 1.6.1.1 Sources, by region
• 1.7 Base estimates and calculations
  • 1.7.1 Revenue share analysis
  • 1.7.2 Base year calculation
• 1.8 Forecast model
• 1.9 Research transparency addendum
  • 1.9.1 Source attribution framework
  • 1.9.2 Quality assurance metrics
  • 1.9.3 Our commitment to trust

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis
• 2.2 Key market trends
  • 2.2.1 Regional trends
  • 2.2.2 Type trends
  • 2.2.3 Gender trends
  • 2.2.4 Distribution channel trends
• 2.3 CXO perspectives: Strategic imperatives
  • 2.3.1 Key decision points for industry executives
  • 2.3.2 Critical success factors for market players
• 2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of hair loss and alopecia
    • 3.2.1.2 Rising consumer awareness and self-care trends
    • 3.2.1.3 Expansion of e-commerce and direct-to-consumer channels
    • 3.2.1.4 Advancements in treatment technologies and clinical research
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Growing availability of alternative treatment options
    • 3.2.2.2 Concerns associated with pharmacological treatments
  • 3.2.3 Market opportunities
    • 3.2.3.1 Rising demand for personalized and precision solutions
    • 3.2.3.2 Growth in combination therapies and adjunct solutions
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
  • 3.4.1 North America
  • 3.4.2 Europe
  • 3.4.3 Asia Pacific
  • 3.4.4 Latin America
  • 3.4.5 Middle East and Africa
• 3.5 Pipeline analysis
• 3.6 Pricing analysis
• 3.7 Future market trends
• 3.8 Porter’s analysis
• 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2025

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Merger and acquisition
  • 4.6.2 Partnership and collaboration
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Type, 2022 - 2035 ($ Mn)

• 5.1 Key trends
• 5.2 Supplements
  • 5.2.1 By product type
    • 5.2.1.1 Single-ingredient supplements
    • 5.2.1.2 Multi-ingredient supplements
  • 5.2.2 By dosage form
    • 5.2.2.1 Powder
    • 5.2.2.2 Gummies
    • 5.2.2.3 Tablets
    • 5.2.2.4 Capsules
    • 5.2.2.5 Liquid
    • 5.2.2.6 Other dosage forms
• 5.3 Pharmaceuticals
  • 5.3.1 Oral medications
  • 5.3.2 Topical and injectables
  • 5.3.3 Devices

Chapter 6 Market Estimates and Forecast, By Gender, 2022 - 2035 ($ Mn)

• 6.1 Key trends
• 6.2 Male
• 6.3 Female

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2022 - 2035 ($ Mn)

• 7.1 Key trends
• 7.2 Hospital pharmacies
• 7.3 E-commerce
  • 7.3.1 Online retailers
  • 7.3.2 Brand-owned websites
• 7.4 Retail pharmacies
• 7.5 Drug stores
• 7.6 Other distribution channels

Chapter 8 Market Estimates and Forecast, By Region, 2022 - 2035 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 India
  • 8.4.3 Japan
  • 8.4.4 Australia
  • 8.4.5 South Korea
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE

Chapter 9 Company Profiles

• 9.1 Hair supplements
  • 9.1.1 Amway Corporation
  • 9.1.2 GNC Holdings
  • 9.1.3 HUM Nutrition
  • 9.1.4 Nature’s Bounty
  • 9.1.5 Nutraceutical Wellness
  • 9.1.6 OUAI Healthcare
  • 9.1.7 Phyto
  • 9.1.8 Viviscal Limited (Church & Dwight)
• 9.2 Hair treatment
  • 9.2.1 Cipla
  • 9.2.2 Curallux
  • 9.2.3 Eli Lilly and Company
  • 9.2.4 ExoCoBio
  • 9.2.5 Keranique
  • 9.2.6 Kenvue
  • 9.2.7 Lexington International
  • 9.2.8 Merck
  • 9.2.9 Pfizer